Skip to main content

Table 4 Sensitivity and specificity of clinical and risk scores to identify individuals with subclinical atherosclerosisa

From: Subclinical atherosclerosis, cardiovascular health, and disease risk: is there a case for the Cardiovascular Health Index in the primary prevention population?

 

Framingham Risk Scored

Metabolic Syndromee

Cardiovascular Health Indexf

 

Intermediate Risk

High Risk

Yes

Average

Inadequate

Sensitivityb

33.9%

(33.8─33.9)

26.6%

(26.5─26.6)

36.7%

(36.6─36.7)

94.8%

(94.7─94.8)

78.0%

(77.8─78.1)

Specificityc

64.9%

(64.8─64.9)

87.4%

(87.3─87.4)

75.3%

(75.2─75.3)

14.9%

(14.8─14.9)

53.2%

(53.1─53.3)

  1. aProportion estimates of the eligible population after applying sampling weights to the study sample (% (95% CI))
  2. bSensitivity: probability of correctly detecting true positive results (individuals who do have subclinical atherosclerosis)
  3. cSpecificity: probability of correctly detecting true negative results (individuals who do not have subclinical atherosclerosis)
  4. dFramingham Risk Score: Intermediate (10–20% 10-year risk) or high risk (> 20% 10-year risk) vs. low risk (referent value; < 10% 10-year risk)
  5. eMetabolic syndrome: Presence of metabolic syndrome (3 or more risk factors) vs. no metabolic syndrome (referent value; < 3 risk factors)
  6. fCardiovascular Health Index (CVHI): Average CV health (5–9 total points) or inadequate CV health (0–4 total points) vs. optimum CV health (reference value; 10–14 total points)
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us